Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
Open Access
- 2 June 2022
- journal article
- research article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 23 (1) , 1-8
Abstract
Background: Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and safety of erenumab in patients with chronic migraine from the outpatient clinic at the Danish Headache Center. Methods: A 52-week, single-center, prospective, observation study of erenumab in adults with chronic migraine who are eligible for treatment with monoclonal antibodies against CGRP or its receptor in Denmark. The primary outcome was defined as proportion of patients who achieved ≥ 30% reduction in monthly migraine days (MMDs) from baseline to weeks 9–12. Results: A total of 300 adult patients with chronic migraine were enrolled and received at least one dose of erenumab. At baseline, the mean (SD) number of monthly headache days was 23 ± 4.9 and mean number of MMDs was 16.8 ± 6.4. Of 300 enrolled patients, 273 (91.0%) patients completed 12 weeks of treatment, and 119 (39.7%) completed 52 weeks of treatment. The number of patients who achieved ≥ 30% reduction in MMDs from baseline to weeks 9–12 was 195 (71.4%) of 273 patients. Sustained ≥ 30% reduction in MMDs at all assessment periods throughout the 52-week treatment period was achieved by 102 (34%) of 300 patients. Adverse events occurred in 220 (73.3%) out of 300 patients. The most common adverse event was constipation. Treatment discontinuation due to lack of tolerability occurred in 41 (13.7%) patients. Conclusions: Among adult patients with chronic migraine and previous failure of medications for migraine prevention, erenumab was found to be effective and well-tolerated.Keywords
This publication has 22 references indexed in Scilit:
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2020
- A prospective real-world analysis of erenumab in refractory chronic migraineThe Journal of Headache and Pain, 2020
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational StudyFrontiers in Neurology, 2020
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central ItalyThe Journal of Headache and Pain, 2020
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension studyCephalalgia, 2020
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adultsCephalalgia, 2018
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraineCephalalgia, 2018
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- A Controlled Trial of Erenumab for Episodic MigraineNew England Journal of Medicine, 2017
- World Medical Association Declaration of HelsinkiJAMA, 2013